Francisco Robert

Summary

Country: USA

Publications

  1. ncbi request reprint Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy
    Ruby Meredith
    Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Cancer Biother Radiopharm 18:393-404. 2003
  2. doi request reprint A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer
    Francisco Robert
    UAB Comprehensive Cancer Center, University of Alabama at Birmingham, 35294 3300, USA
    Cancer Chemother Pharmacol 65:227-34. 2010
  3. pmc Vorinostat in solid and hematologic malignancies
    David Siegel
    Hackensack University Medical Center, Hackensack, NJ, USA
    J Hematol Oncol 2:31. 2009
  4. ncbi request reprint Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer
    F Robert
    Division of Hematology Oncology, Department of Radiation Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, and Birmingham Veterans Administration, 35294 3330, USA
    J Clin Oncol 19:3234-43. 2001
  5. pmc Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
    Francisco Robert
    Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA
    Cancer Chemother Pharmacol 66:669-80. 2010
  6. pmc The potential benefits of low-molecular-weight heparins in cancer patients
    Francisco Robert
    Department of Medicine, Division of Hematology Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 352943300, USA
    J Hematol Oncol 3:3. 2010
  7. ncbi request reprint Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results
    Francisco Robert
    Department of Medicine, Division of Hematology Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, 1824 6th Avenue South, Birmingham, AL 35294 3300, USA
    Lung Cancer 42:237-45. 2003
  8. ncbi request reprint Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: clinical effects and hematologic toxicity
    Francisco Robert
    Department of Medicine, Division of Hematology Oncology and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Cancer Biother Radiopharm 18:317-25. 2003
  9. ncbi request reprint Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial
    Francisco Robert
    Department of Medicine, Division of Hematology Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294 3300, USA
    Lung Cancer 37:189-99. 2002
  10. ncbi request reprint Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer
    Francisco Robert
    University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, AL 35294 3300, USA
    J Clin Oncol 23:9089-96. 2005

Detail Information

Publications22

  1. ncbi request reprint Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy
    Ruby Meredith
    Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Cancer Biother Radiopharm 18:393-404. 2003
    ..Standardization and improved dosimetry may be helpful for comparison among patients in various studies and for establishing dose/toxicity relationships that are useful for predicting safe levels of radioimmunoconjugates...
  2. doi request reprint A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer
    Francisco Robert
    UAB Comprehensive Cancer Center, University of Alabama at Birmingham, 35294 3300, USA
    Cancer Chemother Pharmacol 65:227-34. 2010
    ....
  3. pmc Vorinostat in solid and hematologic malignancies
    David Siegel
    Hackensack University Medical Center, Hackensack, NJ, USA
    J Hematol Oncol 2:31. 2009
    ....
  4. ncbi request reprint Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer
    F Robert
    Division of Hematology Oncology, Department of Radiation Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, and Birmingham Veterans Administration, 35294 3330, USA
    J Clin Oncol 19:3234-43. 2001
    ....
  5. pmc Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
    Francisco Robert
    Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA
    Cancer Chemother Pharmacol 66:669-80. 2010
    ..We assessed the maximum tolerated doses (MTDs), safety, pharmacokinetic profiles, and preliminary efficacy of sunitinib plus docetaxel in patients with advanced solid tumors...
  6. pmc The potential benefits of low-molecular-weight heparins in cancer patients
    Francisco Robert
    Department of Medicine, Division of Hematology Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 352943300, USA
    J Hematol Oncol 3:3. 2010
    ..Such findings reinforce the importance of thromboprophylaxis with low-molecular-weight heparin in cancer patients...
  7. ncbi request reprint Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results
    Francisco Robert
    Department of Medicine, Division of Hematology Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, 1824 6th Avenue South, Birmingham, AL 35294 3300, USA
    Lung Cancer 42:237-45. 2003
    ..This preliminary data suggests that enoxaparin may prolong the time to progression, and therefore justify the continuation of this trial...
  8. ncbi request reprint Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: clinical effects and hematologic toxicity
    Francisco Robert
    Department of Medicine, Division of Hematology Oncology and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Cancer Biother Radiopharm 18:317-25. 2003
    ..Taking into consideration the potential clinical relevance of integration of RIT with other treatment modalities, it is important to expand this clinical experience in order to support combined modality strategies...
  9. ncbi request reprint Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial
    Francisco Robert
    Department of Medicine, Division of Hematology Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294 3300, USA
    Lung Cancer 37:189-99. 2002
    ..The activity observed with this regimen is particularly noteworthy when considering the advanced nature of these patients, and the fact that patients (N=18) with poor risk factors were included in the study...
  10. ncbi request reprint Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer
    Francisco Robert
    University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, AL 35294 3300, USA
    J Clin Oncol 23:9089-96. 2005
    ..Secondary objectives were to gather preliminary evidence of efficacy including tumor response rate, time to progression, and overall survival...
  11. ncbi request reprint Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration
    Andres Forero
    Department of Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, 1824 Sixth Avenue South, Birmingham, AL 35294 3300, USA
    Cancer Biother Radiopharm 20:467-78. 2005
    ....
  12. ncbi request reprint Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer
    Stephen G Divers
    University of Alabama at Birmingham, Birmingham, AL 35294 3300, USA
    J Clin Oncol 23:6664-73. 2005
    ..This is a phase I/IIa study to assess tolerance of gemcitabine and paclitaxel with radiotherapy in locally advanced non-small-cell lung cancer after induction chemotherapy...
  13. ncbi request reprint Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy
    Sui Shen
    Department of Radiation Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama 35249, USA
    J Nucl Med 43:1245-53. 2002
    ..These include (a) recycled (90)Y in bone/marrow space after (90)Y-antibody has been processed in the liver and (b) use of the marrow mass of Reference Man for individual patients...
  14. ncbi request reprint Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men
    Robert James Cerfolio
    Division of Cardiothoracic Surgery, University of Alabama at Birmingham, 1900 University Blvd, THT 712, Birmingham, AL 35294, USA
    Chest 130:1796-802. 2006
    ..National registry-based studies have shown gender disparity in clinicopathologic characteristics and in survival. This study evaluates the risk factors and trends of lung cancer between genders...
  15. doi request reprint Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer
    Joanne Rossman
    Comprehensive Cancer Center, Division of Hematology Oncology, University of Alabama at Birmingham, 1802 Sixth Avenue South, NPCC 2540, Birmingham, AL 35294 3300, United States
    Lung Cancer 72:219-23. 2011
    ....
  16. ncbi request reprint A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy
    Jeffrey Crawford
    Duke Medical Center, Durham, NC 27710, USA
    J Thorac Oncol 2:210-20. 2007
    ....
  17. ncbi request reprint Non-small cell lung cancer
    David S Ettinger
    J Natl Compr Canc Netw 6:228-69. 2008
  18. ncbi request reprint Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer
    Michael P Fanucchi
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
    J Clin Oncol 24:5025-33. 2006
    ..To evaluate the efficacy and toxicity of bortezomib +/- docetaxel as second-line therapy in patients with relapsed or refractory advanced non-small-cell lung cancer (NSCLC)...
  19. ncbi request reprint Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936
    Jonathan D Cheng
    Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 22:602-9. 2004
    ..PNU-214936 is a murine Fab fragment of the monoclonal antibody 5T4 fused to a mutated superantigen staphylococcal enterotoxin A (SEA)...
  20. ncbi request reprint Small cell lung cancer
    Gregory P Kalemkerian
    J Natl Compr Canc Netw 6:294-314. 2008
  21. ncbi request reprint Non-small cell lung cancer clinical practice guidelines in oncology
    David S Ettinger
    J Natl Compr Canc Netw 4:548-82. 2006
  22. ncbi request reprint Small cell lung cancer clinical practice guidelines in oncology
    Bruce E Johnson
    J Natl Compr Canc Netw 4:602-22. 2006